

DAFTAR PUSTAKA

- Abbastabar, H., Rezaianzadeh, A., Rajaeefard, A., dan Ghaem, H., 2016. Determining Factors of CD4 Cell Count in HIV Patients: in a Historical Cohort Study. *International Journal of Life Science & Pharma Research*, **93**: 93–101.
- Abebe, N., Alemu, K., Asfaw, T., dan Abajobir, A.A., 2014. Survival status of hiv positive adults on antiretroviral treatment in Debre Markos Referral Hospital, Northwest Ethiopia: retrospective cohort study. *The Pan African Medical Journal*, **17**: .
- Agosto, L.M., Zhong, P., Munro, J., dan Mothes, W., 2014. Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission. *PLoS Pathogens*, **10**: e1003982.
- AIDSinfo, 2016. 'TB/HIV Considerations for Antiretroviral Use in Patients with Coinfections Mycobacterium Tuberculosis Disease with HIV Coinfection', *AIDSinfo*. URL: <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/27/tb-hiv> (diakses tanggal 8/7/2018).
- Al-Jabri, A.A., 2007. Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS. *Sultan Qaboos University Medical Journal*, **7**: 82–96.
- Allredge, B., Corelli, R., Ernst, M., Guglielmo, B., dan Jacobson, P., 2013. *Koda-Kimble & Young's Applied Therapeutics The Clinical Use of Drugs, 10th Ed.,*. Lippincott Williams & Wilkins, Pennsylvania, United States of America.
- Anderson, P.L., Kakuda, T.N., dan Fletcher, C.N., 2011. Human Immunodeficiency Virus Infection, dalam: *Pharmacotherapy a Pathophysiology Approach*. McGraw Hill Companies, hal. 2171.
- Annison, L., Dompok, A., dan Adu-Sarkodie, Y., 2013. The Immunological Response of Hiv-Positive Patients Initiating Haart at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. *Ghana Medical Journal*, **47**: 164–170.
- Anyebe, E., 2013. Socio-demographic profile of people living with HIV/AIDS (PLWHA) in Idoma land, Benue state, North-central Nigeria: Implications for HIV/AIDS control. *International Journal of Sociology and Anthropology*, **5**: 153–162.
- Ayele, T., Jarso, H., dan Mamo, G., 2017a. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study. *AIDS Research and Therapy*, **14**: .

- Ayele, T., Jarso, H., dan Mamo, G., 2017b. Clinical Outcomes of Tenofovir Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study. *The Open AIDS Journal*, **11**: 1–11.
- Barber, T., Geretti, A.M., dan Anderson, J., 2011. Outcomes in the First Year After Initiation of First -Line HAART among Hetersoseksual Men and Women in the UK CHIC Study. *Antiviral Therapy*, **16**: 805–814.
- Bhatta, L., Klouman, E., Deuba, K., Shrestha, R., Karki, D.K., Ekstrom, A.M., dkk., 2013. Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in far-western Region, 2006–2011. *BMC Infectious Diseases*, **13**: 604.
- Bierman, W.F.W., van Agtmael, M.A., Nijhuis, M., Danner, S.A., dan Boucher, C.A.B., 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. *AIDS (London, England)*, **23**: 279–291.
- Boettiger, D.C., NGUYEN, V.K., DURIER, N., BUI, H.V., SIM, B.L.H., AZWA, I., dkk., 2015. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: Results from the TREAT Asia HIV Observational Database. *Journal of acquired immune deficiency syndromes (1999)*, **68**: 186–195.
- Boffito, M., 2004. From Concept to Care: Pharmacokinetic Boosting of Protease Inhibitors. *the Physicians's Research Network*, **9**: 15–19.
- Bor, J., Herbst, A., Newell, M.-L., dan Barnighausen, T., 2013. Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment. *Science*, **339**: 961–965.
- Brahmachari, U. dan Bhattacharya, R.S., 2014. A Study on Correlation between Opportunistic Infections and CD4 Count in Person Livng with HIV/AIDS. *Conference: 7th National Conference of AIDS Society Of India (ASICON 2014)*, .
- Buehler, M.D. dan Berkelman, M.R.L., 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm. Rep.*, .
- Bunupuradah, T., Chetchotisakd, P., Ananworanich, J., Munsakul, W., Jirajariyavej, S., Kantipong, P., dkk., 2012. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. *Antiviral Therapy*, **17**: 1351–1361

- Castelnuovo, B., John, L., Lutwama, F., Ronald, A., Spacek, L.A., Bates, M., dkk., 2009. Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity. *Journal of the International Association of Physicians in AIDS Care*, **8**: 52–59.
- CDC, 2014. 'Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis', *CDC (Centers for Disease Control and Prevention)*. URL: https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/recommendations02.htm (diakses tanggal 8/7/2018).
- CDC, 2017a. 'About HIV/AIDS', . URL: <https://www.cdc.gov/hiv/basics/whatishiv.html> (diakses tanggal 11/12/2017).
- CDC, 2017b. 'HIV Among men in the United States', *CDC (Centers for Disease Control and Prevention)*. URL: <https://www.cdc.gov/hiv/group/gender/men/index.html> (diakses tanggal 4/7/2018).
- Ciaffi, L., Koulla-Shiro, S., Sawadogo, A., le Moing, V., Eymard-Duvernay, S., Izard, S., dkk., 2015. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa: *AIDS*, **29**: 1473–1481.
- Dadi, T.L., Kefale, A.T., Mega, T.A., Kedir, M.S., Addo, H.A., dan Biru, T.T., 2017. Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis. *AIDS Research and Treatment*, **2017**: 1–7.
- Dalal, R.P., MacPhail, C., Mqhayi, M., Wing, J., Feldman, C., Chersich, M.F., dkk., 2008. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, **47**: 101–107.
- Damtew, B., Mengistie, B., dan Alemayehu, T., 2015. Survival and determinants of mortality in adult HIV/Aids patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. *The Pan African Medical Journal*, **22**: .
- Damtie, D., Yismaw, G., Woldeyohannes, D., dan Anagaw, B., 2013. Common opportunistic infections and their CD4 cell correlates among HIV-infected patients attending at antiretroviral therapy clinic of Gondar University Hospital, Northwest Ethiopia. *BMC Research Notes*, **6**: 534.
- Dash, K.R., Meher, L.K., Hui, P.K., Behera, S.K., dan Nayak, S.N., 2015. High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Southern Odisha. *Indian Journal of Hematology and Blood Transfusion*, **31**: 247–250.

- Depkes RI, 2006. Pedoman Pelayanan Kefarmasian untuk Orang dengan HIV/AIDS (ODHA). *Direktorat Bina Farmasi Komunitas dan Klinik Ditjen Bina Kefarmasian dan Alat Kesehatan Departemen Kesehatan RI*, 36–38.
- Direktur Jenderal Pencegahan dan pengendalian Penyakit, 2017. 'Kajian Epidemiologi HIV Indonesia 2016', . Kementrian Kesehatan Republik Indoneisa, Jakarta.
- Ditjen P2P, 2017. Laporan Situasi Perkembangan HIV-AIDS &PIMS di Indonesia Januari-Maret 2017. *Ditjen P2PKementrian Kesehatan RI*, .
- Dragsted, U.B., Mocroft, A., dan Vella, S., 2004. Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV-1–Infected Adults: A EuroSIDA Study. *Dan Med Bull*, **190**: 371–92.
- Ferradini, L., Ouk, V., Segeral, O., Nouhin, J., Dulioust, A., Hak, C., dkk., 2011. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. *Journal of the International AIDS Society*, **14**: 14.
- Ford, N., Shubber, Z., Hill, A., Vitoria, M., Doherty, M., Mills, E.J., dkk., 2013. Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials. *PLoS ONE*, **8**: e79981.
- Fox, M.P., Ive, P., Long, L., Maskew, M., dan Sanne, I., 2010. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, **53**: 500–506.
- Framm, S.R. dan Soave, R., 1997. Agents of Diarrhea. *Medical Clinics of North America*, **81**: 427–447.
- Gautam, H., Bhalla, P., Saini, S., Uppal, B., Kaur, R., Baveja, C.P., dkk., 2009. Epidemiology of Opportunistic Infections and Its Correlation With CD4 T-Lymphocyte Counts and Plasma Viral Load Among HIV-Positive Patients at a Tertiary Care Hospital in India. *Journal of the International Association of Physicians in AIDS Care*, **8**: 333–337.
- Gezie, L.D., 2016. Predictors of CD4 Count Over Time among HIV Patients Initiated ART in Felege Hiwort Referral Hospital, northwest Ethiopia: Multilevel Analysis. *BMC Research Notes*, **9**: 1–9.
- Hagblom, A., Santacatterina, M., Neogi, U., Gisslen, M., Hejdeman, B., Flamholc, L., dkk., 2017. Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. *PLOS ONE*, **12**: e0180140.

- Handajani, Y.S., Djoerban, Z., dan Irawan, H., 2012. Quality of life people living with HIV/AIDS: outpatient in Kramat 128 Hospital Jakarta. *Acta Med Indones*, **44**: 310–6.
- Harvey, R.A. dan Champe, C., 2014. Obat Antivirus, dalam: *Farmakologi Ulasan Bergambar*. Penerbit Buku Kedokteran EGC.
- Hastuti, 2015. 'Faktor-Faktor yang Berpengaruh Terhadap Peningkatan Sel T CD4+ >350 sel/mm³ dalam 24 Bulan Pertama Menjalani Pengobatan Antiretroviral pada Pasien HIV', . Universitas Gadjah Mada, Yogyakarta.
- Heil, E.L., Trezza, C., dan Corbett, A.H., 2016. Human Immunodeficiency Virus Infection, dalam: *Pharmacotherapy Principles & Practice*. McGraw Hill Education.
- Highleyman, L., 2015. 'CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?', *HIVandHepatitis.com*. URL: <http://www.hivandhepatitis.com/hiv-treatment/approved-hiv-drugs/5128-croi-2015-does-emtricitabine-work-better-than-lamivudine-in-combination-art> (diakses tanggal 10/7/2018).
- Hosseinipour, M., Kumwenda, J., Weigel, R., Brown, L., Mzinganjira, D., Mhango, B., dkk., 2010. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. *HIV Medicine*, .
- Hosseinipour, M.C., van Oosterhout, J.J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., dkk., 2009. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy: *AIDS*, **23**: 1127–1134.
- Huang, P., Tan, J., Ma, W., Zheng, H., Lu, Y., Wang, N., dkk., 2015. Long-Term Effectiveness of Antiretroviral Therapy in China: An Observational Cohort Study from 2003–2014. *International Journal of Environmental Research and Public Health*, **12**: 8762–8772.
- Hunt, K., Mondal, P., Konrad, S., Skinner, S., Gartner, K., dan Lim, H.J., 2015. Identifying factors associated with changes in CD4+ count in HIV-infected adults in Saskatoon, Saskatchewan. *The Canadian Journal of Infectious Diseases & Medical Microbiology*, **26**: 207–211.
- Israelski, D., Gore-Felton, C., Power, R., Wood, M.J., dan Koopman, C., 2001. Sociodemographic Characteristics Associated with Medical Appointment Adherence among HIV-Seropositive Patients Seeking Treatment in a County Outpatient Facility. *Preventive Medicine*, **33**: 470–475.

- Jensen-Fangel, S., 2004. The effectiveness of highly active antiretroviral therapy in HIV-infected patients. *Dan Med Bull*, **51**: 371–92.
- Johnson, L., Mossong, J., Dorrington, R., Schomaker, M., Hoffmann, C.J., Keiser, O., dkk., 2012. Life expectancies of HIV-positive adults receiving antiretroviral treatment in South Africa. *Actuarial Society of South Africa's*,
- Kalayjian, R.C., Landay, A., Pollard, R.B., Taub, D.D., Gross, B.H., Francis, I.R., dkk., 2003. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. *The Journal of infectious diseases*, **187**: 1924–1933.
- Kefale, A.T., Dadi, T.L., Biru, T.T., dan Mega, T.A., 2018. Treatment Outcome and Adverse Events of Tenofovir Disoproxil Fumarate Based Regimens as Compared to Zidovudine Based Regimens Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis of Observational Studies. *The Open AIDS Journal*, **12**: 38–52.
- Kementrian Kesehatan RI, 2011. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa dan Remaja. *Kementrian kesehatan RI Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan*, .
- Kementrian Kesehatan RI, 2015. Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 Tentang Pedoman Pengobatan Antiretroviral.
- Kiio, S.N., 2010. 'Treatment Outcomes of Second Line Antiretroviral Therapy in Mbagathi District Hospital Comprehensive Care Clinic', , *Disertasi*, . University of Nairobi, Kenya.
- Kitahata, M.M., Gange, S.J., Abraham, A.G., Merriman, B., Saag, M.S., Justice, A.C., dkk., 2009. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. *The New England journal of medicine*, **360**: 1815–1826.
- Klein, R.S., Harris, C.A., Small, C.B., Moli, B., Lesser, M., dan Friedland, G.H., 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome **311**: 354–8.
- Kulkarni, S.V., Kairon, R., Sane, S.S., Padmawar, P.S., Kale, V.A., Thakar, M.R., dkk., 2009. Opportunistic parasitic infections in HIV/AIDS patients presenting with diarrhoea by the level of immunesuppression. *Indian Journal of Medical Research*, **130**: 63.

- Kumarasamy, N., Aga, E., Ribaud, H.J., Wallis, C.L., Katzenstein, D.A., Stevens, W.S., dkk., 2015. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. *Clinical Infectious Diseases*, .
- Kumarasamy, N., Patel, A., dan Pujari, S., 2011. Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
- Latif, F., Maria, I.L., dan Syafar, M., 2014. Efek Samping Obat terhadap Kepatuhan Pengobatan Antiretroviral Orang dengan HIV/AIDS. *Kesmas: National Public Health Journal*, **9**: 101–106.
- Lebouché, B., Yazdanpanah, Y., Gérard, Y., Sissoko, D., Ajana, F., Alcaraz, I., dkk., 2006. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. *HIV medicine*, **7**: 140–145.
- Leger, P., Charles, M., Severe, P., Riviere, C., dan Pape, J.W., 2009. 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. *The New England Journal of Medicine*, **361**: 828–929.
- Lemeshow, S., Hosmer Jr., D.W., Klar, J., dan Lwanga, S.K., 1997. *Besar Sampel dalam Penelitian Kesehatan*, 1st ed. Gadjah Mada University Press, Yogyakarta.
- Leth, F. van, Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., dan Gazzard, B., 2004. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. *Lancet*, **363**: 1253–1263.
- Levison, J.H., Orrell, C., Losina, E., Lu, Z., Freedberg, K.A., dan Wood, R., 2011. Early Outcomes and the Virological Effect of Delayed Treatment Switching to Second-Line Therapy in an Antiretroviral Roll-out Programme in South Africa. *Antiviral Therapy*, **16**: 853–861.
- Li, R. dan Gossman, W.G., 2017. *CD4 Count*. StatPearls Publishing.
- Lv, R., Li, G., Wu, J., Zhu, Y., Qin, X., dan Li, S., 2016. Research on AIDS patients' survival time after highly active antiretroviral therapy, treatment effect and treatment modes. *Saudi Pharmaceutical Journal*, , Current Research in Chemical and Pharmaceutical Sciences **24**: 318–321.

- MacArthur, R.D. dan DuPont, H.L., 2012. Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era. *Clinical Infectious Diseases*, **55**: 860–867.
- Machado-Alba, J.E. dan Vidal, X., 2012. Effectiveness of antiretroviral treatment in Colombia. *Revista Panamericana de Salud Pública*, **32**: 360–367.
- Maskew, M., Brennan, A.T., Westreich, D., McNamara, L., MacPhail, A.P., dan Fox, M.P., 2013. Gender Differences in Mortality and CD4 Count Response Among Virally Suppressed HIV-Positive Patients. *Journal of Women's Health*, **22**: 113–120.
- Maskew, M., MacPhail, P., Menezes, C., dan Rubel, D., 2007. Lost to follow up-contributing factors and challenges in South African patients on antiretroviral therapy. *South African Medical Journal*, **97**: 853–857.
- May, M.T., Vehreschild, J.-J., Trickey, A., Obel, N., Reiss, P., Bonnet, F., dkk., 2016. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **62**: 1571–1577.
- May Myat Win, Maek-a-nantawat, W., Phonrat, B., Kiertiburanakul, S., dan Sungkanuparph, S., 2011. Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. *Journal of the International Association of Physicians in AIDS Care*, **10**: 57–63.
- Megerso, A., Garoma, S., Eticha, T., Workineh, T., Daba, S., Habtamu, Z., dkk., 2016. Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region, Ethiopia. *HIV/AIDS - Research and Palliative Care*, **83**.
- Meintjes, G., Black, F., Conradie, F., Dlamini, S., dan Fabian, J., 2014. Guideline Adult Antiretroviral Therapy Guidelines 2014 by the Southern African HIV Clinicians Society. *SAJHIVMED*, **15**: 121–143.
- Meintjes, G., Moorhouse, M.A., Carmona, S., Davies, N., Dlamini, S., Van Vuuren, C., dkk., 2017. Adult antiretroviral therapy guidelines 2017. *Southern African Journal of HIV Medicine*, **18**: 1–24.
- Mocroft, A., Phillips, A.N., Miller, V., Gatell, J., van Lunzen, J., Parkin, J.M., dkk., 2001. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. *Aids*, **15**: 201–209.

- Mocroft, A.J., Lundgren, J.D., d'Armino Monforte, A., Ledergerber, B., Barton, S.E., Vella, S., dkk., 1997. Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. *International journal of epidemiology*, **26**: 400–407.
- Modi, J.P., Kubavat, A., Mundhava, S., dan Lalwani, U., 2018. A Prospective Study to Evaluate Prescription Pattern of Second Line Antiretroviral Therapy Given to HIV Patients. *Journal of Young Pharmacists*, **10**: 117–122.
- Mohammed, S., Berheto, T., dan Haile, D., 2014. Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. *North American Journal of Medical Sciences*, **6**: 453.
- Morgan, D., Mahe, C., Mayanja, B., Okongo, J.M., Lubega, R., dan Whitworth, J.A., 2002. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? *Aids*, **16**: 597–603.
- Mosha, F., Muchunguzi, V., Matee, M., Sangeda, R.Z., Vercauteren, J., Nsubuga, P., dkk., 2013. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. *BMC Public Health*, **13**: 38.
- Murphy, R.A., Sunpath, H., Castilla, C., Ebrahim, S., Court, R., Nguyen, H., dkk., 2012. Second-Line Antiretroviral Therapy: Long-Term Outcomes in South Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, **61**: 158–163.
- Nasronudin, 2014. *HIV & AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial*, 2nd ed. Airlangga University Press, Surabaya.
- Nasronudin, 2015. Infeksi HIV, dalam: *Buku Jar Ilmu Penyakit Dalam*. Airlangga University Press, Surabaya, hal. 677–678.
- Nguyen, N. dan Holodniy, M., 2008. HIV infection in the elderly. *Clinical Interventions in Aging*, **3**: 453–472.
- Okki, R., 2010. 'Pengaruh efek samping antiretroviral lini pertama HIV dan AIDS Rumah Sakit Cipto Mangunkusumo (RSCM)', , AIDS-INA.
- Olowookere, S.A., Fatiregun, A.A., Ladipo, M.M.A., Abioye-Kuteyi, E.A., dan Adewole, I.F., 2016. Effects of adherence to antiretroviral therapy on body mass index, immunological and virological status of Nigerians living with HIV/AIDS. *Alexandria Journal of Medicine*, **52**: 51–54.
- Omeregic, R., Egbeobauwaye, A., Ogefere, H., Omokaro, E., dan Ekeh, C., 2008. Prevalence of antibodies to HAART agents among HIV patients in Benin City, Nigeria. *African Journal of Biomedical Research*, **11**: .

- Osinusi-Adekanmbi, O., Stafford, K., Ukpaka, A., Salami, D., Ajayi, S., Ndembu, N., dkk., 2014. Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, **13**: 366–371.
- Pantaleo, G., Graziosi, C., dan Fauci, A.S., 1993. The Immunopathogenesis of Human Immunodeficiency Virus Infection. *The New England Journal of Medicine*, **328**: 329.
- Paton, N., Kityo, C., dan Hoppe, A., 2013. 'Boosted PI (Kaletra) + NNRTIs Successful as 2nd-Line ART in Africa: EARNEST Study - "A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial"', . URL: http://www.natap.org/2013/IAS/IAS_84.htm (diakses tanggal 12/12/2017).
- Pau, A.K. dan George, J.M., 2014. Antiretroviral Therapy. *Infectious Disease Clinics of North America*, **28**: 371–402.
- Pokala, N. dan Patel, M., 2016. Efficacy of Second line Anti-retroviral therapy among HIV/AIDS patients in south India: A Prospective Observational study. *International Journal of Pharmacology and Clinical Sciences*, **5**: 73–76.
- Pujades-Rodríguez, M., Balkan, S., Arnould, L., Brinkhof, M.A., dan Calmy, A., 2010. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. *Jama*, **304**: 303–312.
- Pujades-Rodriguez, M., O'brien, D., Humblet, P., dan Calmy, A., 2008. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. *Aids*, **22**: 1305–1312.
- Pusdatin Kementerian Kesehatan RI, 2016. Situasi Penyakit HIV AIDS di Indonesia. *Pusat Data dan Informasi Kementerian Kesehatan RI*, .
- Pusdatin Kementerian Kesehatan RIa, 2017. Data dan Informasi Profil Kesehatan Indonesia 2016. *Pusat Data dan Informasi Kementerian Kesehatan RI*, .
- Rai, S., Mahapatra, B., Sircar, S., Raj, P.Y., Venkatesh, S., Shaukat, M., dkk., 2013. Adherence to Antiretroviral Therapy and Its Effect on Survival of HIV-Infected Individuals in Jharkhand, India. *PLoS ONE*, **8**: e66860.
- Reda, A.A., Biadgilign, S., Deribew, A., Gebre, B., dan Deribe, K., 2013. Predictors of Change in CD4 Lymphocyte Count and Weight among HIV Infected Patients on Anti-Retroviral Treatment in Ethiopia: A Retrospective Longitudinal Study. *PLoS ONE*, **8**: e58595.

- Reddy, K.Y., Visalakshi, B., dan Kirankumar, P., 2015. Immunological Response of Human Immunodeficiency Virus Positive Patients after Initiation of Highly Active Antiretroviral Therapy. *Age (years)*, **12**: 12–60.
- Rosen, S., Fox, M.P., dan Gill, C.J., 2007. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. *PLoS medicine*, **4**: e298.
- Scarsi, K.K., Eisen, G., Darin, K.M., Meloni, S.T., Rawizza, H.E., Tchetgen, E.T., dkk., 2016. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, **62**: 512–518.
- Second Line Group, 2013. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. *The Lancet*, **381**: 2091–2099.
- Seyoum, A., Ndlovu, P., dan Temesgen, Z., 2017. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region). *AIDS Research and Therapy*, **14**: .
- Shet, A., Costa, A.D., Kumarasamy, N., Rodrigues, R., Rewari, B.B., Ashorn, P., dkk., 2014. Effect of mobile telephone reminders on treatment outcome in HIV: evidence from a randomised controlled trial in India. *BMJ*, **347**: g5978–g5978.
- Silverberg, M.J., Leyden, W., Horberg, M.A., DeLorenze, G.N., Klein, D., dan Quesenberry, C.P., 2007. Older age and the response to and tolerability of antiretroviral therapy. *Archives of internal medicine*, **167**: 684–691.
- Singh dan Bairy I, 2003. Spectrum of opportunistic infections in AIDS cases. *Indian Journal of Medical Sciences*, **57**: 16–21.
- Siripassorn, K., Manosuthi, W., Chottanapund, S., Pakdee, A., Sabaitae, S., Prasithsirikul, W., dkk., 2010. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. *AIDS research and human retroviruses*, **26**: 139–148.

- Sobrin-Vegas, P., Rodriguez-Johana, J., dan Berenguer, J., 2012. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. *Antiviral Therapy*, **17**: 1–8.
- Subbaraman, R., Chaguturu, S.K., Mayer, K.H., Flanigan, T.P., dan Kumarasamy, N., 2007. Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries. *Clinical Infectious Diseases*, **45**: 1093–1101.
- Sulkowski, M.S., Mast, E.E., Seeff, L.B., dan Thomas, D.L., 2000. Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. *Clinical Infectious Diseases*, **30**: S77–S84.
- Sumintarti dan Rasdiana, A., 2014. Manifestasi klinis tipe kandidiasis oral pada penderita AIDS di Rumah Sakit Dr Wahidin Sudirohusodo, Makassar. *Dentofasial*, **13**: 185–188.
- Tatro, D.S., 2009. *Drug Interaction Facts*. Wolters Kluwer Health.
- Tegegne, A.S., Ndlovu, P., dan Zewotir, T., 2018. Determinants of CD4 cell count change and time-to default from HAART; a comparison of separate and joint models. *BMC Infectious Diseases*, **18**: .
- Touloumi, G., Pantazis, N., Stirnadel, H.A., Walker, A.S., Boufassa, F., Vanhems, P., dkk., 2008. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, **49**: 492–498.
- UNAIDS, 2018. 'Indonesia | UNAIDS', . URL: <http://www.unaids.org/en/regionscountries/countries/indonesia> (diakses tanggal 14/1/2018).
- UNAIDS, A., 2017. Unaid Data 2017. *Joint United Nations Programme on HIV/AIDS (UNAIDS)*, , UNAIDS/JC2910E.
- Volberding, P.A. dan Deeks, S.G., 2010. Antiretroviral therapy and management of HIV infection. *The Lancet*, 376: 49–62.
- WHO, 1969. 'International Drug Monitoring: The Role of the Hospital. Technical Report Series No. 425', , dalam: *WHO Meeting on the Role of the Hospital in International Drug Monitoring*. WHO, Geneva.
- WHO, 2015. Fact Sheet HIV Treatment and Care What's New in Monitoring WHO/HIV/2015.42: .
- WHOa, 2017. HIV Treatment and Care What's New in Treatment Monitoring: Viral Load and CD4 Testing WHO/HIV/2017.22: .

Wingfield, T. dan Wilkins, E., 2010. Opportunistic infections in HIV disease. *British Journal of Nursing*, 19: 621–627.

Wong, N., Lee, M., Lee, P., dan Lee, S., 2012. Differential patterns of CD4 recovery following effective treatment with HAART. *Journal of the International AIDS Society*, 15: 1–1.

World Health Organization, 2012. *Patient Evaluation and Antiretroviral Treatment for Adults and Adolescents Clinical Protocol for the WHO European Region (2012 Revision)*. World Health Organization Regional Office for Europe, Copenhagen, Denmark.

World Health Organization, 2016. *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing Hiv Infection: Recommendations for a Public Health Approach*.

World Health Organization, World Health Organization, dan Department of HIV/AIDS, 2010. *Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach*.

Wuan, A.O., 2017. 'Faktor-Faktor yang Mempengaruhi Peningkatan Jumlah Sel CD4 pada Pasien HIV dengan Terapi Antiretroviral di Kupang Nusa Tenggara Timur', . Universitas Gadjah Mada, Yogyakarta.

Yuliandra, Y., Nosa, U.S., Raveinal, R., dan Almasdy, D., 2017. Terapi Antiretroviral pada Pasien HIV/AIDS di RSUP. Dr. M. Djamil Padang: Kajian Sociodemografi dan Evaluasi Obat. *Jurnal Sains Farmasi & Klinis*, 4: 1.

Zaragoza-Macias, E., Cosco, D., Nguyen, M.L., del Rio, C., dan Lennox, J., 2010. Predictors of Success with Highly Active Antiretroviral Therapy in an Antiretroviral-Naive Urban Population. *AIDS Research and Human Retroviruses*, 26: 133–138.